Portfolio
Our solution
Complex solution for Alzheimer´s disease therapy. Development from idea to real solution.
- Three different drug substances by now (Agora 1, Agora 2, Agora 3).
- Different approach to treat Alzheimer´s disease in each of them.
- Targeting different Alzheimer’s disease pathways with our drug candidates to minimize the failure.
Phase | Primary goal | Dose | Patient monitor | Typical number of participants | Success rate |
---|---|---|---|---|---|
Preclinical | Testing of drug in non-human subjects, to gather information on efficacy, safety and pharmacokinetics | Unrestricted | Scientific researcher | Not applicable (in vitro and animal studies only) | |
Phase 1 | Testing of drug on healthy volunteers for safety and pharmakokinetics | Starting at subtherapeutic dose, but with ascending to therpeutic levels | Clinical researcher | 20–100 normal/ elderly healthy volunteers | Approx. 70% |
Phase 2 | Testing of drug on patients to assess safety / tolerability; first assesmaent of efficacy | Therapeutic dose | Clinical researcher | 100–300 patients with specific diseases | Approx. 33% |
Phase 3 | Testing of drug on patients to assess efficacy and safety | Therapeutic dose | Clinical researcher and personal physician | 300–3,000 patients with specific diseases | 25–30% |